Pioneering the future of nuclear defense.

USIL Therapeutics is pioneering next-generation medical countermeasures against ionizing radiation, delivering whole-body protection and lifesaving treatments for both civilian and defense applications.
Our Mission

Protecting Lives Against Radiation Threats

USIL Therapeutics pioneers breakthrough medical solutions to safeguard people from the dangers of ionizing radiation. Our mission is to transform radiation defense with treatments and potential cures that go beyond symptomatic care, delivering true whole-body protection. Partnering with governments, defense, and energy sectors worldwide, we provide scalable, effective countermeasures that strengthen resilience and global preparedness in the face of nuclear and radiological risks.
Contact us
Contact us

Radiation Protection Worldwide

We are pioneering next-generation medical countermeasures to safeguard populations, critical infrastructure, and strategic sectors from the threats of ionizing radiation.
€10M+ Assets
Our asset base is anchored by a portfolio of patented molecules designed to become the world’s first-in-class radioprotectors by 2031. Backed by decades of validated research and clinical models, these patents combine scientific excellence with strong commercial potential.
Global Reach
We collaborate with governments, defense agencies, and healthcare systems across continents. By combining advanced science with international partnerships, we ensure radiation protection is scalable, deployable, and resilient in civilian and defense settings.
10+ Experts
Our team brings over 25 years of expertise in radiobiology, pharmaceuticals, defense, and large-scale manufacturing. Backed by leading scientists and regulatory specialists, we deliver the innovation and execution to bring countermeasures to market.

Nuclear Defense as a Global Emergency

Governments and agencies in the US and EU have declared nuclear defense and radiation protection a critical priority. Rising geopolitical tensions, renewed nuclear strategies, and expanding civilian energy programs underscore the urgent need for effective countermeasures. USIL Therapeutics addresses this recognized global emergency with patented solutions designed to protect populations and strengthen resilience.

Products in Development

We are advancing two breakthrough formulations, UT-241 and UT-242, currently in development to deliver next-generation protection against ionizing radiation.

UT-241 (Syringe)
RAPID-RESPONSE RADIATION COUNTERMEASURE
UT-241 is an easy-to-use, ready-to-deploy injectable designed for rapid intervention in critical field situations — from nuclear accidents to battlefront emergencies. It provides immediate, whole-body protection against ionizing radiation. Portable, stable, and simple to administer, UT-241 ensures reliable defense for military, energy, and first-responder operations where speed and simplicity are vital.
UT-242 (IV Infusion)
EXTENDED WHOLE-BODY RADIOPROTECION
UT-242 is an intravenous infusion therapy designed for comprehensive, long-lasting protection against ionizing radiation. Intended for hospitals, field clinics, and specialized defense settings, it safeguards all major organ systems during high-risk exposure events. Scalable and adaptable, UT-242 strengthens resilience for both civilian and military operations where extended care is essential.

Our Partners

Core Team & Advisory Board

Fred Marin
CEO & CO-FOUNDER
Pharm.D. by training, entrepreneur with 20+ years’ experience leading multifunctional, multicultural teams in diverse industries.
Bruno Le Grand
CSO & CO-FOUNDER
PhD, pharmacology and drug development expert with 35 years’ experience in biopharma and healthcare.
Bruno Flamion
CRO & CO-FOUNDER
MD, PhD, former Chair of the Scientific Advice Working Party at the European Medicines Agency (EMA).
Michel Andraud
CFO & CO-FOUNDER
CFO with 30+ years’ experience in finance and M&A across international industrial groups.
‍
Jean-Alexandre Kaminsky
HEAD OF SALES
EMBA, MedTech executive with 20+ years’ experience in Medical Devices (hardware & software solutions).
Catherine Federspiel
HEAD OF ADMIN
15+ years’ experience in international consulting, aligning strategy and operations to optimize performance.
Valentin Wiedling
INVESTOR RELATIONS
Entrepreneur, Harvard-trained, with 15+ years’ experience in investor relations and scaling international ventures.
Jose Morente
HEAD OF MANUFACTURING
International executive with 25+ years’ experience in automotive with focus on manufacturing.
Alain Rodermann
INVESTMENT ADVISOR
VC leader with 27+ years’ experience, founder of Expon Capital, driving deeptech and innovation across Europe.
Stefan Dimitrov-Lübcke
SPACE ADVISOR
Yuri LUX CEO, expert in payloads to Low Earth Orbit with 20+ years in technology regulation and life sciences business development.

Why Partner with USIL Therapeutics?

USIL Therapeutics is addressing one of the world’s most urgent unmet medical needs: protection against ionizing radiation. With patented molecules, validated efficacy, and a regulatory fast-track underway, we are uniquely positioned to become a global leader in radiation countermeasures.

Headquartered in Luxembourg, an EU and NATO hub with direct access to defense supply chains, global logistics, and European space and health programs, we benefit from partnerships with ESA, leading research institutions, and industry leaders. Together with strategic partners and investors, we aim to scale dual-use medical countermeasures and bring life-saving solutions to market at the heart of international security and innovation.

Publications

Influence of the Nucleo-Shuttling of the ATM Protein on the Response of Skin Fibroblasts from Marfan Syndrome to Ionizing Radiation

This pioneering study applies the RIANS model to skin fibroblasts from Marfan syndrome patients, revealing impaired DNA damage response due to cytoplasmic ATM sequestration—driven by mutated FBN1 and elevated TGF‑β—unveiling a new molecular basis for radiosensitivity in connective tissue disorders. Click here to access this publication.

Molecular Influence of the ATM Protein in the Treatment of Human Cells with Different Radioprotective Drugs: Comparisons between Antioxidative and Pro-Episkevic Strategies

This study compares antioxidative and pro-episkevic approaches, showing how ATM protein activity critically shapes the effectiveness of radioprotective drugs in safeguarding human cells from ionizing radiation. Click here to access this publication.

Skin Fibroblasts from Individuals Self-Diagnosed as Electrosensitive Reveal Two Distinct Subsets with Delayed Nucleoshuttling of the ATM Protein in Common

Fibroblasts from individuals self-reporting electrosensitivity revealed two distinct subgroups, both marked by delayed ATM protein nucleoshuttling — highlighting a shared molecular mechanism underlying their radiosensitivity. Click here to access this publication.

Accelerated Aging Effects Observed In Vitro after an Exposure to Gamma-Rays Delivered at Very Low and Continuous Dose-Rate Equivalent to 1–5 Weeks in International Space Station

Human cells exposed to very low, continuous gamma radiation—mimicking 1–5 weeks aboard the ISS—showed accelerated aging effects, offering vital insights for astronaut health and long-term space missions. Click here to access this publication.

Get in touch

Whether you are a government agency, industry partner, or healthcare provider, we’re here to answer your questions and explore collaboration opportunities.
Name
Email
Phone
Company
Message
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking “Ok, Got It”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Ok, got it